• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

Mirati - oncology?

















Mirati Therapeutics (NASDAQ:MRTX) shareholders have endured a 57% loss from investing in the stock three years ago


Mirati Therapeutics (NASDAQ:MRTX) shareholders have endured a 57% loss from investing in the stock three years ago

If you love investing in stocks you're bound to buy some losers. Long term Mirati Therapeutics, Inc.(NASDAQ:MRTX) shareholders know that all too well, since the share price is down considerably over three years. Regrettably, they have had to cope with a 57% drop in the share price over that period. The more recent news is of little comfort, with the share price down 52% in a year. Unfortunately the share price momentum is still quite negative, with prices down 9.1% in thirty days.
 




Mirati Therapeutics (NASDAQ:MRTX) shareholders have endured a 57% loss from investing in the stock three years ago


Mirati Therapeutics (NASDAQ:MRTX) shareholders have endured a 57% loss from investing in the stock three years ago

If you love investing in stocks you're bound to buy some losers. Long term Mirati Therapeutics, Inc.(NASDAQ:MRTX) shareholders know that all too well, since the share price is down considerably over three years. Regrettably, they have had to cope with a 57% drop in the share price over that period. The more recent news is of little comfort, with the share price down 52% in a year. Unfortunately the share price momentum is still quite negative, with prices down 9.1% in thirty days.

Meek and his bad toupee must go.